- Trials with a EudraCT protocol (3,326)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (6)
3,326 result(s) found for: Type II.
Displaying page 1 of 167.
EudraCT Number: 2022-002316-23 | Sponsor Protocol Number: CKJX839C12001B | Start Date*: 2023-01-16 | |||||||||||
Sponsor Name:Novartis Farmacéutica, S.A. | |||||||||||||
Full Title: An open-label, single arm, multicenter extension study to evaluate long-term safety and tolerability of inclisiran in participants with heterozygous or homozygous familial hypercholesterolemia who... | |||||||||||||
Medical condition: Familial Hypercholesterolemia | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) IT (Ongoing) NO (Trial now transitioned) DE (Ongoing) NL (Trial now transitioned) HU (Ongoing) GR (Trial now transitioned) FR (Ongoing) SI (Ongoing) PL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-001023-21 | Sponsor Protocol Number: DRL-17822/CD/004 | Start Date*: 2011-06-30 | |||||||||||
Sponsor Name:DR. REDDY'S LABORATORIES LIMITED | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate Efficacy, Safety and Tolerability of DRL-17822 in Patients with Type II Hyperlipidemia | |||||||||||||
Medical condition: Hyperlipidemia Type II | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-000582-37 | Sponsor Protocol Number: CHOL00107 | Start Date*: 2007-09-21 | |||||||||||
Sponsor Name:Genzyme Europe BV | |||||||||||||
Full Title: A Phase 4 Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Centre Study of Colesevelam as Add-on Therapy in Patients with Familial Hypercholesterolaemia | |||||||||||||
Medical condition: Familial hypercholesterolaemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) FR (Completed) DE (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-002848-41 | Sponsor Protocol Number: CAPL180A2207 | Start Date*: 2008-08-07 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A randomized, double-blind, placebo-controlled ascending dose study to evaluate the effect of APL180 on endothelial function in patients with familial hypercholesterolemia | |||||||||||||
Medical condition: familial hypercholesterolemia | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-002743-27 | Sponsor Protocol Number: TKT024EXT | Start Date*: 2004-12-23 | |||||||||||
Sponsor Name:Shire Human Genetic Therapies INC. | |||||||||||||
Full Title: An Open-Label Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Iduronate-2-Sulfatase Enzyme Replacement Therapy | |||||||||||||
Medical condition: Mucopolysaccharidosis Type II (MPS II or Hunter Syndrome) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male | ||||||||||||
Trial protocol: DE (Completed) GB (Completed) SE (Completed) IT (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-003321-28 | Sponsor Protocol Number: LTS13769 | Start Date*: 2014-05-12 | ||||||||||||||||
Sponsor Name:Genzyme Corporation | ||||||||||||||||||
Full Title: An Open-Label, Multicenter, Multinational Extension Study Of The Long-Term Safety And Pharmacokinetics Of Repeated Biweekly Infusions Of Avalglucosidase Alfa (NeoGAA, GZ402666) In Patients With Pom... | ||||||||||||||||||
Medical condition: Pompe disease (acid alpha-glucosidase deficiency) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: BE (Completed) NL (Completed) DK (Completed) DE (Completed) FR (Ongoing) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2014-004143-13 | Sponsor Protocol Number: SHP-609-302 | Start Date*: 2015-03-19 | ||||||||||||||||
Sponsor Name:Shire Human Genetic Therapies, Inc. | ||||||||||||||||||
Full Title: An Open Label Extension of Study HGT-HIT-094 Evaluating Long Term Safety and Clinical Outcomes of Intrathecal Idursulfase Administered in Conjunction with Elaprase® in Patients with Hunter Syndrome... | ||||||||||||||||||
Medical condition: Hunter syndrome and cognitive impairment | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) ES (Ongoing) FR (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-002168-59 | Sponsor Protocol Number: AGLU017-02 | Start Date*: 2004-10-14 | |||||||||||
Sponsor Name:GENZYME | |||||||||||||
Full Title: An Open-Label, Multicenter, Multinational, Study of the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Recombinant Human Acid alpha- Glucosidase (rhGAA) Treatment in Patients > 6 and <... | |||||||||||||
Medical condition: Treatment for Type II Glycogenosis | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-004047-25 | Sponsor Protocol Number: ALGMYL08718 | Start Date*: 2021-07-27 | |||||||||||
Sponsor Name:Sanofi(China) Investment Co Ltd, Shanghai Branch | |||||||||||||
Full Title: A Single Arm, Prospective, Open-label, Multi-center Study to Evaluate Efficacy and Safety in Chinese Patients with Infantile-Onset Pompe Disease with One Year Alglucosidase Alfa Treatment | |||||||||||||
Medical condition: Infantile-Onset Pompe Disease | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-000212-25 | Sponsor Protocol Number: HGT-HIT-046 | Start Date*: 2012-01-05 | |||||||||||
Sponsor Name:Shire HGT Inc | |||||||||||||
Full Title: An Open-Label Extension of Study HGT-HIT-045 Evaluating Long-Term Safety and Clinical Outcomes of Intrathecal Idursulfase-IT Administered in Conjunction with Intravenous Elaprase® in Pediatric Pati... | |||||||||||||
Medical condition: Treatment of Hunter syndrome and cognitive impairment | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) Outside EU/EEA | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-003595-38 | Sponsor Protocol Number: AT845-01 | Start Date*: 2020-11-20 | |||||||||||
Sponsor Name:Audentes Therapeutics, Inc. | |||||||||||||
Full Title: FORTIS: A Phase 1/2, Open-Label, Ascending-Dose Clinical Study to Evaluate the Safety and Preliminary Efficacy of AT845, an AAV8-Delivered Gene Transfer Therapy in Patients with Late Onset Pompe Di... | |||||||||||||
Medical condition: Late Onset Pompe Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-005552-11 | Sponsor Protocol Number: LTS12869 | Start Date*: 2022-03-07 | |||||||||||
Sponsor Name:Genzyme Corporation | |||||||||||||
Full Title: A Long-term Study to Evaluate Growth and Development Outcomes in Patients With Infantile-Onset Pompe Disease Who Are Receiving Alglucosidase Alfa. | |||||||||||||
Medical condition: Pompe disease | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-000007-17 | Sponsor Protocol Number: TAK-875_309 | Start Date*: 2013-06-05 | |||||||||||||||||||||||||||||||
Sponsor Name:Takeda Global Research & Development Centre (Europe) Ltd. | |||||||||||||||||||||||||||||||||
Full Title: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, 24-Week Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 50mg Compared With Placebo as an Add-On to Glimepiride ... | |||||||||||||||||||||||||||||||||
Medical condition: Type 2 diabetes mellitus (T2DM) | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: SK (Prematurely Ended) HU (Prematurely Ended) BG (Prematurely Ended) PL (Prematurely Ended) | |||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2015-004003-23 | Sponsor Protocol Number: ISIS703802 | Start Date*: 2016-09-28 | |||||||||||||||||||||
Sponsor Name:Ionis Pharmaceuticals, Inc. | |||||||||||||||||||||||
Full Title: A Placebo-Controlled, Dose-Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of ISIS 703802, Targeting ANGPTL3, Administered S... | |||||||||||||||||||||||
Medical condition: Heterozygous familial hypercholesterolemia and Homozygous familial hypercholesterolemia | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: IT (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2008-008296-33 | Sponsor Protocol Number: 1218.36 | Start Date*: 2009-06-29 | ||||||||||||||||||||||||||
Sponsor Name:Boehringer Ingelheim Finland Ky | ||||||||||||||||||||||||||||
Full Title: A Phase III randomised, double-blind, placebo-controlled, parallel group efficacy and safety study of Linagliptin (5 mg), administered orally once daily for at least 52 weeks in type 2 diabetic pa... | ||||||||||||||||||||||||||||
Medical condition: Type 2 diabetes pretreated with basal Insulin therapy | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: FI (Completed) DE (Completed) NL (Completed) ES (Completed) SK (Completed) BE (Completed) CZ (Completed) IT (Completed) SE (Completed) GR (Completed) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2007-006044-22 | Sponsor Protocol Number: HGT-ELA-038 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Shire Human Genetic Therapies, Inc. (Shire HGT) | |||||||||||||
Full Title: A Multi-Center, Open-Label Study Evaluating Safety and Clinical Outcomes in Hunter Syndrome Patients 5 Years of Age and Younger Receiving Idursulfase Enzyme Replacement Therapy | |||||||||||||
Medical condition: Mucopolysaccharidosis Type II (MPS II or Hunter Syndrome) | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Children, Under 18 | Gender: Male | ||||||||||||
Trial protocol: PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-004686-39 | Sponsor Protocol Number: EFC14462 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Sanofi-Aventis Recherche & Développement | |||||||||||||
Full Title: An Open-label, Multinational, Multicenter, Intravenous Infusion Study of the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of avalglucosidase alfa in Treatment naïve Pediatric Participan... | |||||||||||||
Medical condition: Glycogen storage disease type II | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) BE (Ongoing) NL (Ongoing) IT (Ongoing) Outside EU/EEA ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-001752-10 | Sponsor Protocol Number: TAK-875_302 | Start Date*: 2012-10-30 | |||||||||||||||||||||||||||||||
Sponsor Name:Takeda Global Research & Development Centre (Europe) Ltd. | |||||||||||||||||||||||||||||||||
Full Title: A Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of TAK-875 25 mg and 50 mg Compared to Placebo and Sitagliptin 100 mg When... | |||||||||||||||||||||||||||||||||
Medical condition: Type 2 diabetes mellitus (T2DM) | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: HU (Prematurely Ended) CZ (Prematurely Ended) SK (Prematurely Ended) BG (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2011-001789-16 | Sponsor Protocol Number: PenCTU/2011/CTIMP-005 | Start Date*: 2011-08-26 | |||||||||||
Sponsor Name:Plymouth Hospital NHS Trust | |||||||||||||
Full Title: Investigation of the intra-tumoural concentration and activity of sorafenib in cutaneous schwannomas | |||||||||||||
Medical condition: Neurofibromatosis, type 2 (acoustic neurofibromatosis) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-002741-35 | Sponsor Protocol Number: TAK-875_301 | Start Date*: 2012-02-15 | ||||||||||||||||||||||||||
Sponsor Name:Takeda Global Research & Development Centre (Europe) Ltd. | ||||||||||||||||||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 mg and 50 mg Compared with Placebo in Subjects with Type 2 Diabetes | ||||||||||||||||||||||||||||
Medical condition: Type 2 diabetes mellitus (T2DM) | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: SK (Completed) HU (Completed) BG (Completed) | ||||||||||||||||||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.